Aurora Spine Corporation (ASAPF) generates a steady stream of news around its spinal implant platforms, biologics portfolio, and participation in medical and investor events. The company’s releases highlight developments in minimally invasive spine surgery, interventional pain management, and bone density–matched implant technology.
Recent announcements emphasize Aurora Spine’s DEXA Technology platform, including the DEXA-C cervical fusion system and the DEXA-L anterior lumbar interbody fusion device, which the company describes as bone-mimicking implants engineered to match a patient’s bone density and quality. Other news focuses on the SiLO Sacroiliac Joint Fusion System, which Aurora reports has been used in more than 2,500 procedures, and the AERO Lumbar Fusion System, a minimally invasive facet fusion device cleared for use from C2 to S1.
Investors and clinicians following ASAPF news will also see updates on Aurora Biologics, a division dedicated to allograft-based biologic solutions designed to support spinal fusion and work in concert with the company’s mechanical implants. Patent issuances, such as those covering the ZIP implant family and bone density scan–matched orthopedic implants, further illustrate Aurora’s focus on intellectual property around spinal implant design.
This news feed captures product launches, clinical usage milestones, conference participation at meetings like NASS and ASPN, and scheduled financial result releases and investor presentations. Users can monitor these updates to understand how Aurora Spine presents the evolution of its spine technologies, surgeon adoption, and broader corporate activities over time.
Aurora Spine Corporation (TSXV: ASG, OTCQB: ASAPF) announced its participation in the Lytham Partners Spring 2021 Investor Conference on March 30, 2021, at 1:15 PM ET. The company's President & CEO, Trent Northcutt, and CFO, Chad Clouse, will present and engage in virtual one-on-one meetings from March 30 to April 1, 2021. A live webcast of the presentation will be accessible on their website, with an archived version available later. Aurora Spine focuses on innovative spinal implant technologies and pain management solutions.
Aurora Spine Corporation announced the launch of its proprietary SiLO™ Posterior SI Joint Fusion System, designed for posterior sacroiliac joint fusion. This innovative system aims to enhance surgical outcomes through a single graft method made of human cortical bone. The Company also released a biomechanical whitepaper demonstrating that the SiLO graft effectively immobilizes the sacroiliac joint better than traditional rectangular grafts. The SI joint fusion market is projected to grow significantly, with an estimated value of $150 million to $250 million globally in 2019, indicating a high potential for Aurora's growth.
Aurora Spine Corporation announced that its common shares are now trading on the OTCQB Venture Market under the symbol ASAPF, enhancing accessibility for US investors. This move is aimed at improving Aurora's status as a publicly traded company and boosting investor awareness, which the company began in 2020. The management foresees this listing as timely, coinciding with plans to launch several new proprietary products in 2021.
For more information, visit OTC Markets.